Girotti et al. observed a significant reduction in the proliferation of melanoma cells in vitro and in vivo using gefitinib (EGFR and ERBB2 inhibitor) and PLX4720 (BRAF V600E inhibitor), as well as employing dasatinib (tyrosine kinase inhibitor with broad specificity) monotherapy [25]. This evidence concerns the gene ERBB2 and melanoma.